NCT06608186CompletedPhase 1/2
Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!
Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS Cases
Source: ClinicalTrials.gov · Last updated 22 Jan 2025
Brief summary (registry, in English)
The goal of this clinical trial is to learn if drospirenone can work to prevent LH surge in controlled ovarian stimulation in PCOS cases undergoing ART cycles. The main questions it aims to answer are: Can drospirenone prevent LH surge in controlled ovarian stimulation in PCOS cases ? Can it prevent the occurance of ovarian hyperstimulation? Researchers will compare drospirenone to cetrorelix (A well known drug for such cases) to see if drospirenone works the same way. Participants will: Take drospirenone or cetrorelix from stimulation day 5 ( 5 days of ovarian stimulation) till day of hCG trigger \- monitoring will be done before the cycle and through the cycles with vaginal ultrasound assessment and lab testing
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 19 Sept 2024
- Start date
- 1 Oct 2024
- Primary completion date
- 19 Jan 2025
- Lead sponsor
- Ahmed Saad
- NCT number
- NCT06608186
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 50
- From 1 Oct 2024 to the primary completion date, 19 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous ovarian surgery
Age
- age 38 years
Other
- basal FSH level 12 mIU/mL
- congenital uterine anomaly anomaly, intrauterine adhesion and male partner with non-obstructive azoospermia.
Who the study is looking for
- PCOS was diagnosed according to the Rotterdam consensus criteria (two out of three of the following criteria):
- oligo- or anovulation
- clinical and/or biochemical signs of hyperandrogenism
- polycystic ovaries).
- A diagnosis of congenital adrenal hyperplasia, Cushing's syndrome, androgen-producing tumours, hyperprolactinemia and thyroid dysfunction were all rulled out.
Age in the registry: 20 years to 38 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hawaa Fertility center Coordinator of this site? Confirm its status | Banhā | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.